Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 7MW4911 |
| Synonyms | |
| Therapy Description |
7MW4911 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH17 linked to MF-6, which potentially inhibits growth of CDH17-expressing tumors (PMID: 40602407). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 7MW4911 | 7MW-4911|7MW 4911 | 7MW4911 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH17 linked to MF-6, which potentially inhibits growth of CDH17-expressing tumors (PMID: 40602407). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07216560 | Phase Ib/II | 7MW4911 | First-in-human Study of 7MW4911 in GI Cancer | Recruiting | USA | 0 |